Prelude Therapeutics Incorporated

US$3.60As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:PRLDHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (29.39%)
Div yield —
ROE (57.73%)
Biotechnology
Beta (5Y) 1.19
PE TTM —
TSR TTM 126.42%
Mkt cap US$370.8M
ROIC (33.70%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$4.31
19.79%
(96.34%)
Hold 11|9|7|1|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.05
0.06
0.06
0.07
15.78%
20.80%
20.36%
31.00%
Revenue$M
17.50
17.76
17.28
18.27
7.53%
10.43%
2.18%
3.74%
Peers (US$370.8M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
1.776
0.640
0.676
EBIT/Intx
0.175
0.258
0.240
Own earn%
(138.05)
(239.49)
(140.01)
Sh yield%
52.68
47.68
49.55
Owners
Insiders/Inst%
11.71
66.72
Short interest%
5.19
SBC / revenue%
5.39
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
8
Op margin range%
14–24
$1 testx
0.0
Incr. ROIC%
9